Analysts' Actions: AGN FB KMB SO WEN

NEW YORK ( TheStreet) --

Saul Centers ( BFS) was downgraded to sell at TheStreet Ratings.

Allergan ( NOK) was downgraded at Goldman Sachs. Valuation call, based on a $110 price target, Goldman said.

Big Lots ( BIG) was downgraded to hold at TheStreet Ratings.

CH Robinson ( CHRW) was downgraded at Goldman Sachs to sell from neutral. $56 price target. Light truck names should lag the broader group, Goldman said.

Facebook ( FB) was upgraded at UBS to buy from neutral. Price target goes to $30. Current valuation is low and new monetization efforts are encouraging, UBS said.

Forest Laboratories ( FRX) was upgraded at Goldman Sachs to buy from neutral. $50 price target. See a higher potential for management to explore strategic options, Goldman said.

Fulton Financial ( FULT) was downgraded at Credit Suisse to underperform from neutral. $9.50 price target. Expect negative revisions to mortgage banking estimates, Credit Suisse said.

Kimberly-Clark ( KMB) was upgraded at BMO Capital Markets to market perform from underperform. Valuation call, based on a $96 price target, BMO Capital Markets said.

Medicines Company ( MDCO) was downgraded at Oppenheimer to perform from outperform. New analyst believes the stock is fully valued, Oppenheimer said.

Netgear ( NTGR) was upgraded at Wedbush to outperform from neutral. $38 price target. Company has potential catalysts for the second half and 2014, Wedbush said.

Questcor ( QCOR) was downgraded at Bank of America/Merrill Lynch to neutral from buy. $51 price target. Acthar could face increased competition, BofA/Merrill said.

Questcor was upgraded at Oppenheimer to outperform from perform. $57 price target. New analyst believes that Acthar can drive near-term growth, Oppenheimer said.

Southern Company ( SO) was upgraded at Citigroup to buy from neutral. The GP rate case will be manageable, and Vogtle cost overruns do not present a structural issue, Citi said.

SPX ( SPW) was downgraded at Citigroup to sell from neutral. Price target is $68. There is significant second half earnings risk and valuation is elevated, Citigroup said.

Total System ( TSS) was upgraded to outperform at Wells Fargo. Company shows unanticipated FCF growth and trades at a cheap multiple, Wells Fargo said.

Wendy's ( WEN) was initiated with a market perform rating at Wells Fargo. Company shows low EV/EBITDA relative its peers, but is inhibited by less-than-expected margin expansion, Wells Fargo said.

STOCK COMMENTS/EPS CHANGES

FirstMerit ( FMER) numbers were raised at UBS. Estimates were increased to reflect the earlier-than-expected closing of the CRBC acquisition, said UBS. Price target goes to $22.

Corning ( GLW) numbers were reduced at UBS. Reflect LCD panel price declines and volume reductions, said UBS. Price target goes to $16.50.

Oracle ( ORCL) numbers were reduced at UBS. Earnings estimates were cut given a weak macro and concerns about the shift to the cloud and sales execution, said UBS. Price target goes to $37.

Oracle estimates were cut at Citigroup. Earnings estimates were reduced given macro weakness, said Citigroup. Price target remains $38.

Oracle estimates, price target were reduced at Oppenheimer. Shares are now seen reaching $37. Estimates were also cut, as the company is not executing well, Oppenheimer said. Outperform rating.

Supervalu ( SVU) numbers were raised at Citigroup. Opportunity for cost savings and SG&A leverage, said Citigroup. Price target goes to $7.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Allergan Exec on Medical Aesthetics: 'The Future Is About Market Expansion'

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Purdue Pharma to Downplay Opioids, Dump 50% of Sales Staff

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget